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Hyperlipidemia can induce or aggravate renal
tubulointerstitial injury. Experiments in a complex rat model
with chronic glomerulonephritis and long-standing,
coexisting hyperlipidemia suggested that induction of
xanthine oxidase (XO), with increased oxygen radical
generation, is involved in aggravation of tubulointerstitial
injury. To separate the role of XO in the initial events of
lipid-mediated tubulointerstitial injury, short-term
experiments with diet-induced hyperlipidemia over 21 and
35 days were performed in otherwise healthy rats. XO
expression in relation to the antioxidant enzymes was
examined in the cortical tubulointerstitium (TIS) and proximal
tubules (PT). Subsequent experiments with XO inhibition
were performed, examining tubulointerstitial infiltration with
ED1-positive cells and expression of adhesion molecules and
monocyte chemoattractant protein-1 (MCP-1) as indicators of
early injurious events. Hyperlipidemia increased XO activity in
TIS by 40 and 86%, and in PT by 28 and 90% at days 21 and
35, compared with controls on regular diet. This increased
activity was associated with increased reactive oxygen
species. Among the antioxidant enzymes, glutathione
peroxidase activity increased in TIS by 40% and in PT by 90%.
Histological evaluation showed a three-fold increase in
ED1-positive cells and increased MCP-1 and vascular cell
adhesion molecule-1 (VCAM-1) expression at day 35 in the
TIS. Inhibition of XO prevented tubulointerstitial ED1 cell
infiltration, together with a decreased expression of MCP-1
and VCAM-1. These results point to an important role for XO
in the early stage of hyperlipidemia-associated renal injury,
mediating macrophage infiltration by a putatively
redox-dependent upregulation of MCP-1 and VCAM-1.
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Hyperlipidemia is common in patients with chronic renal
failure. Some clinical studies have suggested that hyperlipi-
demia in patients with renal disease may act as a modulating
factor that contributes to progressive renal impairment.1–4
This is supported by diverse experimental studies showing
increased glomerular and tubulointerstitial damage and
macrophage infiltration, higher protein excretion, and
accelerated loss of renal function in hyperlipidemic ani-
mals.5–7 Demonstration of oxidatively modified lipids in the
kidney and renal protective effects with vitamin E supple-
mentation suggested that oxidative injury is involved in the
mechanisms of lipid-mediated tissue damage.5,8
We have recently examined the long-term effects of
hyperlipidemia in rats with chronic anti-Thy1 glomerulone-
phritis.9 Compared with nephritic animals without hyperli-
pidemia, animals with nephritis and hyperlipidemia over a
period of 70 and 150 days showed accelerated glomerulo-
sclerosis and tubulointerstitial damage, including tubular
atrophy and tubulointerstitial macrophage infiltration and
fibrosis. Accelerated renal injury was associated with an
increased generation of reactive oxygen species (ROS) and a
decrease in intrinsic antioxidant enzyme activities in the
tubulointerstitium. Moreover, oxidatively modified proteins
were detected in renal tissue, indicative of oxidative stress
and injury. As the major cause of increased ROS generation,
we identified xanthine oxidase. The activity of this
oxidase was two- to three-fold higher in the tubulointer-
stitium, together with increased quantities of the enzyme as
determined by Western blot analysis. Based on these
results, xanthine oxidase-dependent oxidative pathogenetic
mechanisms could play an important role in hyperlipi-
demia-mediated renal damage. However, as our previous
studies were performed in a complex model with unine-
phrectomy and glomerulonephritis and at an advanced stage
of renal injury, we could not determine whether xanthine
oxidase is involved in the initial sequence of changes in the
tubulointerstitium caused by hyperlipidemia. Therefore, the
present study examines the isolated and early effect of
hyperlipidemia on xanthine oxidase expression and tubu-
lointerstitial changes in rats without other coexisting renal
pathologies.
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RESULTS
Basic data (Table 1)
The high-fat and high-cholesterol diet resulted in a
significant increase in cholesterol and triglyceride serum
levels. Serum creatinine levels and urinary protein excretion
were unchanged in hyperlipidemic animals. Tubular atrophy
and tubulointerstitial fibrosis were absent in controls and
hyperlipidemic animals (not shown). Staining for ED1-
positive cells revealed a moderate increase in infiltrating cells
in the cortical tubulointerstitium of the animals with
hyperlipidemia. Taken together, these minor changes in-
dicated an early stage of lipid-mediated renal alterations.
Reactive oxygen species and the expression of xanthine
oxidase and antioxidant enzymes
Chemiluminescence (CL) measurements in tubulointerstitial
samples and in specifically isolated proximal tubules with
luminol, a general detector of ROS, indicated an increased
generation of ROS in both tissue fractions of hyperlipidemic
animals (Figure 1a). CL with lucigenin was increased in the
tubulointerstitial fraction at day 35, indicating an involve-
ment of superoxide anion radical (Figure 1b).
Increased ROS generation was associated with higher
activities of xanthine oxidase in the tubulointerstitium and in
proximal tubules (Figure 2). Further evaluation of xanthine
oxidase expression in proximal tubules by Western and
Northern blotting revealed increased protein and mRNA
levels of the enzyme in hyperlipidemic animals (Figure 3). By
immunohistochemistry, xanthine oxidase expression was
localized in the peritubular area, most probably correspond-
ing to peritubular capillaries in controls and in hyperlipi-
demic animals. In addition, animals with hyperlipidemia
showed staining of xanthine oxidase in tubular epithelial cells
and in the vicinity of mononuclear cells infiltrating the region
of peritubular capillaries (Figure 4).
Despite increased ROS generation, there were only minor
changes in the expression of antioxidant enzymes in
Table 1 | Laboratory and immunohistochemistry data in
experimental animals
Controls HLP 21 days HLP 35 days
Cholesterol in serum (mg/dl) 7179 107732** 107719**
(n=17) (n=8) (n=8)
Triglycerides in serum (mg/dl) 36718 81735* 60717*
(n=16) (n=8) (n=8)
Serum creatinine (mg/dl) 0.5070.04 0.5270.02 0.5570.05
(n=17) (n=6) (n=7)
Protein excretion (mg/24 h) 19.377.3 18.376.2 15.375.2
(n=17) (n=8) (n=8)
ED1-positive cells 3.270.8 6.172.3** 9.976.2**
(number/high-power field)a (n=17) (n=8) (n=8)
Controls: animals with standard diet. HLP 21 days and HLP 35 days: hyperlipidemic
animals on a fat- and cholesterol-enriched diet for 21 or 35 days, respectively. Values
are means7s.d.; *Po0.05 vs controls; **Po0.01 vs controls.
aMagnification:  400.
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Figure 1 | CL measurements in the cortical tubulointerstitium and
in proximal tubules of control animals with standard diet (n¼ 17)
and hyperlipidemic animals fed a fat- and cholesterol-enriched
diet for 21 days (HLP-d21, n¼ 8) or 35 days (HLP-d35, n¼ 8). (a)
Luminol-enhanced CL as a general indicator of ROS. (b) Lucigenin-
enhanced CL for specific detection of superoxide anion radical.
*Po0.05 vs controls; **Po0.01 vs controls.
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Figure 2 | Xanthine oxidase activity in the cortical tubulointer-
stitium and in proximal tubules of control animals with standard
diet (n¼ 17) and hyperlipidemic animals fed a fat- and
cholesterol-enriched diet for 21 days (HLP-d21, n¼ 8) or 35 days
(HLP-d35, n¼ 8). *Po0.05 vs controls; **Po0.01 vs controls.
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Figure 3 | Levels of xanthine oxidoreductase (XOR) mRNA and
protein in proximal tubules of control animals with standard diet
and hyperlipidemic animals (HLP) fed a fat- and cholesterol-
enriched diet for 35 days. Results are representative of
independent analyses of four samples from the controls and six
samples from hyperlipidemic animals. (a) Levels of XOR mRNA are
shown in relation to the 28S RNA of the samples. Relative optical
densities for XOR mRNA after correction for 28S RNA abundance were
1.070.3 in the control samples and 1.470.2 in the samples from
animals with hyperlipidemia. (b) XOR protein bands are shown in
relation to the internal loading control b-tubulin. Splitted protein
bands correspond to the two major fragments of XOR, which are
present under reducing conditions.10 Relative optical densities for
XOR after correction for b-tubulin abundance were 1.970.4 in the
control samples and 3.070.5 in the samples from animals with
hyperlipidemia. Right lane: molecular weight marker proteins.
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tubulointerstitial and proximal tubular samples of hyperlipi-
demic animals (Figure 5). Total activities of superoxide
dismutase (SOD) (i.e. copper/zinc SOD and manganese
SOD), manganese SOD activities alone, as well as catalase
activities remained virtually unchanged. Of note, glutathione
peroxidase showed an increased activity in hyperlipidemic
animals that was maximal in proximal tubules after 35 days
of high-fat and high-cholesterol diet.
Inhibition of xanthine oxidase: effect on early tubulointer-
stitial changes
Based on the putative role of intercellular adhesion molecule-
1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1),
and monocyte chemoattractant protein-1 (MCP-1) in the
tubulointerstitial infiltration with macrophages in hyperlipi-
demia5,11,12 and the reported ROS-dependent regulation of
these factors,13–15 we hypothesized that xanthine oxidase
might be involved in the process of macrophage infiltration
in our model. Therefore, experiments were performed with
animals in which xanthine oxidase had been inhibited by
administration of tungsten.
Tungsten treatment did not significantly change cholester-
ol and triglyceride serum levels in animals fed a high-
cholesterol and high-fat diet (cholesterol: 95720 vs
94724 mg/dl, triglycerides 90729 vs 152788 mg/dl in
animals without and with tungsten treatment, respectively).
In Figure 6, the efficient inhibition of xanthine oxidase by
tungsten is shown in animals with and without feeding a
high-fat and high-cholesterol diet over 35 days. Inhibition of
xanthine oxidase in animals with hyperlipidemia was
associated with a significant decrease in the number of
ED1-positive cells infiltrating the cortical tubulointerstitium
(Figure 7). Staining of renal tissues for ICAM-1 revealed no
substantial changes between animals on a standard diet and
hyperlipidemic rats with and without xanthine oxidase
inhibition (not shown). Compared with the normolipemic
controls, hyperlipidemic animals without xanthine oxidase
a b
Figure 4 | Immunohistology for xanthine oxidase in the cortical
tubulointerstitium. (a) In the controls without hyperlipidemia,
xanthine oxidase staining is present in the peritubular region. (b) In
animals with hyperlipidemia, increased xanthine oxidase expression
is detected in the tubular epithelium, in the peritubular area probably
corresponding to peritubular capillaries, and in the vicinity of
mononuclear cells (arrows). Original magnification  400.
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Figure 5 | Activities of the antioxidant enzymes in the cortical
tubulointerstitium and in proximal tubules of control animals
with standard diet (n¼ 17) and hyperlipidemic animals fed a fat-
and cholesterol-enriched diet for 21 days (HLP-d21, n¼ 8) or 35
days (HLP-d35, n¼ 8). t-SOD: total SOD, consisting of copper/zinc
SOD and manganese SOD (MnSOD) activity. Numericals in parenth-
eses within the columns indicate smaller sample numbers available
for analysis. *Po0.05 vs controls; **Po0.01 vs controls.
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Figure 6 | Xanthine oxidase activity in the cortical tubulointer-
stitium and in proximal tubules of control animals with standard
diet, either with (n¼ 5) or without (n¼ 8) administration of the
xanthine oxidase inhibitor tungsten, and of hyperlipidemic
animals (HLP) fed a fat- and cholesterol-enriched diet for 35
days, either with (n¼ 11) or without (n¼ 11) administration of
tungsten. *Po0.05 vs controls; **Po0.01 vs controls.
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Figure 7 | Number of ED1-positive cells in the cortical tubuloin-
terstitium of control animals with standard diet, either with
(n¼ 5) or without (n¼ 8) administration of the xanthine oxidase
inhibitor tungsten, and of hyperlipidemic animals (HLP) fed a fat-
and cholesterol-enriched diet for 35 days, either with (n¼ 11) or
without (n¼ 11) administration of tungsten. **Po0.01 vs control
groups and hyperlipidemic animals with tungsten treatment.
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inhibition showed intense and continuous circumferential
staining for VCAM-1 at the endothelial side of interlobular
arteries. Also, increased staining was present in the
peritubular interstitium, most probably corresponding to
the peritubular capillaries. In hyperlipidemic animals in
which xanthine oxidase had been inhibited, increased
peritubular VCAM-1 expression was clearly reduced and
interlobular arteries showed discontinuous VCAM-1 staining
at the endothelial side (Figure 8). MCP-1 staining in the
peritubular interstitium was increased in hyperlipidemic
animals as compared with the normolipemic controls. In
hyperlipidemic animals with xanthine oxidase inhibition,
MCP-1 staining was diminished, as shown in Figure 9.
DISCUSSION
Based on recent observations in a model with long-standing
hyperlipidemia in uninephrectomized rats with glomerulo-
nephritis,9 this study examined whether xanthine oxidase has
a role in the early phase of hyperlipidemia-mediated renal
alterations. Different to previous experimental studies, which
examined lipid-associated renal injury in accelerated models
with uninephrectomy and glomerulonephritis,5,7–9 we chose
to study the isolated and early effects of diet-induced
hyperlipidemia using rats without glomerular disease or
reduced renal mass. Analysis of serum creatinine and protein
excretion, and morphological evaluation of renal tissues
confirmed that hyperlipidemic animals were, in fact, at an
early stage of renal alterations. Obvious changes were limited
to a moderate tubulointerstitial infiltration with ED1-positive
cells, whereas tubular atrophy and tubulointerstitial fibrosis
were absent. Similar subtle renal alterations have been
reported previously in hyperlipidemic rats without coexisting
glomerular disease or renal mass reduction.16
Analysis of renal tissues in hyperlipidemic animals
demonstrated an increased xanthine oxidase activity and
generation of ROS. Apparently, induction of xanthine
oxidase by hyperlipidemia particularly includes increased
expression in proximal tubules as indicated by higher
activities and higher protein and mRNA levels of the enzyme
in this tissue fraction, besides the expression of xanthine
oxidase in the area of peritubular capillaries observed in the
immunohistological studies. The mechanisms by which
hyperlipidemia induced xanthine oxidase in proximal tubules
are unclear. A previous study in cultured human renal
proximal tubular cells showed cellular uptake of non-
oxidized lipoproteins with subsequent metabolism in a
superoxide anion radical-dependent reaction. However, the
involved oxidase was not specified.17 Yet, studies in arterial
vessels of rabbits with hypercholesterolemia demonstrated
increased ROS generation by xanthine oxidase.18,19
Analysis of antioxidant enzymes revealed increased
glutathione peroxidase activity in proximal tubular and
tubulointerstitial samples. Such increased enzyme expression
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Figure 8 | (a and b) Immunohistology for VCAM-1 in the controls
on a standard diet, (c and d) and in hyperlipidemic animals
without (e and f) and with inhibition of xanthine oxidase.
Controls show a very weak positivity for VCAM-1 (a) at the
endothelial side of interlobular arteries and (b) in the peritubular
area. In hyperlipidemic animals, (c) continuous circumferential
staining of interlobular arteries and (d) intense staining of the
peritubular area is present (arrows), besides increased glomerular
staining. Hyperlipidemic animals with xanthine oxidase inhibition
show (e) discontinuous VCAM-1 staining of interlobular arteries and
(f; arrows) decreased VCAM-1 staining of the peritubular area.
Original magnification:  400.
a b c
Figure 9 | Immunohistology for MCP-1 in the controls on a
standard diet, and in hyperlipidemic animals without and with
inhibition of xanthine oxidase. Compared with the controls, (a)
which show weak staining for MCP-1 in the peritubular region, (b;
arrows) hyperlipidemic animals without xanthine oxidase inhibition
exhibit a pronounced MCP-1 staining in the peritubular interstitium.
(c) This peritubular staining (arrow) is clearly decreased in hyperlipi-
demic animals with xanthine oxidase inhibition. Original magnifica-
tion  400.
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could represent a protective mechanism by which renal cells
intercept the detrimental effects of lipid peroxides, as
suggested by studies in cultured endothelial and renal
proximal tubular cells.20,21 Activities of SOD were un-
changed, despite increased superoxide anion radical genera-
tion in renal samples of hyperlipidemic animals. Based on
these results, it can be concluded that the antioxidant enzyme
defense was not sufficiently upregulated by the increased load
of ROS. Such inadequate response of the antioxidant
enzymatic defense system to oxidative stress is in keeping
with observations in several animal models of renal diseases
as recently summarized.22
Hyperlipidemia has been reported to induce upregulation
of the adhesion molecules ICAM-1 and VCAM-1 and of the
chemokine MCP-1 in the kidney, factors that are important
in the recruitment and attraction of macrophages.5,11,12
Moreover, the expression of these factors was shown to be
regulated by ROS.13–15 This led to the hypothesis that
hyperlipidemia-mediated xanthine oxidase expression might
induce these factors, which, in turn, facilitated the increased
macrophage infiltration in the kidney. Therefore, experi-
ments were performed with animals in which xanthine
oxidase had been inhibited by administration of tungsten.
Tungsten is an inhibitor that incorporates into the active
center of the enzyme in place of molybdenum during
enzyme synthesis, resulting in a non-functional xanthine
oxidase.23
In hyperlipidemic animals with tungsten treatment, a
profound inhibition of xanthine oxidase activity was
documented in the cortical tubulointerstitium and in
proximal tubules, along with a significant reduction of ED-
1-positive cells in the cortical tubulointerstitium compared
with hyperlipidemic animals without tungsten treatment.
The reversal of this cell infiltration in hyperlipidemic animals
with xanthine oxidase inhibition strongly suggests that
xanthine oxidase indeed induces mediator pathways leading
to the recruitment and attraction of infiltrating cells. Of the
known mediators, expression of VCAM-1 and MCP-1 was
found to be upregulated specifically in the peritubular area
and for VCAM-1, in interlobular arteries, similar to
previously reported results.5,11,12 Based on the reduced
VCAM-1 and MCP-1 expression in hyperlipidemic animals,
in which xanthine oxidase inhibition prevented the infiltra-
tion with ED1-positive cells, these two molecules may be of
particular importance in this model. The essential role of
MCP-1 in the recruitment of macrophages and development
of atherosclerotic lesions has been convincingly demonstrated
in hyperlipidemic mice genetically deficient in MCP-1.24
Once tubulointerstitial infiltration with macrophages is
established, the further pathophysiological sequence may
include local secretion of tumor growth factor-b and other
mediators, eventually resulting in tubular atrophy and
tubulointerstitial fibrosis as described earlier.5,9
A pivotal question however is how these experimental
observations apply to humans with hyperlipidemia. Cautious
interpretation is necessary because of the known differences
in lipid metabolism between rats and man. Rats have higher
high-density lipoprotein cholesterol levels, and cholesterol-
and fat-enriched diet induces increases in cholesterol-
containing very low density lipoprotein and low-density
lipoprotein particles.6,9 Disturbances of lipid metabolism in
patients with chronic renal disease are characterized by an
increase of mainly triglyceride-containing intermediate
lipoprotein and low-density lipoprotein particles and a
decrease in high-density lipoprotein cholesterol.25 So far, in
patients with hyperlipidemia, a clearcut involvement of
oxidative injury has been established only in lipid-induced
arterial disease,26,27 and xanthine oxidase may be essential in
this process.28,29 With regard to renal diseases, an association
between hyperlipidemia and an accelerated renal impairment
has been noted in several studies, but evidence for a causal
relationship is still scarce. On the other hand, recently
conducted prospective studies in patients with chronic
kidney disease of different etiologies could identify increased
serum triglyceride and low-density lipoprotein cholesterol
levels as independent risk factors that favor a progressive
course of the renal disease.3,4 In patients with a renal
allograft, dyslipidemia with decreased high-density lipopro-
tein cholesterol serum levels was identified as a major risk
factor for tubulointerstitial deposition of oxidized low-
density lipoprotein cholesterol, infiltration with macro-
phages, and fibrosis.30 Moreover, hyperlipidemic patients
with a renal allograft seem to have a higher risk of acute
rejections and chronic allograft dysfunction.31–33 As upregu-
lation of MHC class I and II molecules in renal syngrafts34
and in endothelial cells has been shown to depend on redox-
sensitive mechanisms,35 it is tempting to speculate that lipid-
induced xanthine oxidase expression may be involved in this
process. Taken together, these findings indicate that hyper-
lipidemia or dyslipidemia has a role in the progression of
human renal disease and allograft deterioration, albeit to a
lesser extent than in animal models, in which hyperlipidemia
can cause renal injury even in the absence of pre-existing
renal disease.16
It remains to be evaluated whether lipid-lowering
therapies can lessen the progression of renal disease in
patients with hyperlipidemia.36,37 Further studies are neces-
sary to establish whether oxidative mechanisms are ope-
rative in the tissue injury of hyperlipidemic patients with
renal disease, and whether xanthine oxidase is involved in
this. Such insights could help to determine whether
inhibition of oxidases or administration of antioxidants
may be additional therapeutical options besides lipid-
lowering therapy.
MATERIALS AND METHODS
Animals and basic procedures
Male Wistar rats (10–12 weeks old at the beginning of the study;
Charles River, Sulzfeld, Germany) were fed either a standard rat
chow (Altromin 1324; Lage, Germany) or a high-fat (40%) and
high-cholesterol (5%) diet over 21 or 35 days. The high-fat and
high-cholesterol diet was supplemented with 0.35% (w/w) cholic
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acid (Sigma Chemicals, St Louis, MO, USA) to enhance the enteral
absorption of lipids and cholesterol. The diets have been described
in detail.6 In two separate groups of animals, the xanthine oxidase
inhibitor tungsten (Sigma Chemicals)38 was added to the drinking
water (700 mg/l) 3 weeks prior to feeding the two different diets and
was maintained until the killing of the animals.
After feeding the different diets for 21 or 35 days, kidneys were
harvested to isolate the cortical tubulointerstitium and proximal
tubules and to obtain samples for histological analyses. Before
isolation of renal tissues, 24-h urine collections were made for
protein determination. Blood samples for the determination of
creatinine, cholesterol, and triglyceride levels were obtained by
cardiac puncture after killing of the animals and measurements were
performed using automatic analyzers (Beckman Instruments,
Munich, Germany). Protein concentration in urinary samples was
analyzed according to Lowry et al.39 All procedures on animals were
conducted in accordance with the American Physiological Society’s
Guiding Principles in the Care and Use of Animals and with the
permission of the local governmental authorities.
Preparation of renal tissues
Animals were killed by cervical dislocation. Kidneys were flushed
with 20 ml of ice-cold Krebs–Henseleit-saline buffer via an aortal
catheter. A slice of kidney was fixed in methacarn solution (60%
methanol, 30% chloroform, and 10% acetic acid) for 8 h and
embedded in paraffin. Additional kidney slices were frozen in liquid
nitrogen and subsequently stored at 801C. Cortices of the kidneys
were taken for the isolation of the tubulointerstitium by gradual
sieving, and for isolation of proximal tubules using collagenase
digestion and gradient centrifugation in Percoll (Pharmacia,
Freiburg, Germany), as previously described in detail.40 Freshly
isolated samples were immediately subjected to the determination of
ROS. The remaining samples were further processed for the analysis
of enzyme activities and Western and Northern blotting as
previously described40 and stored at 801C until use.
Measurement of reactive oxygen species
Generation of ROS in freshly prepared renal samples was examined
by luminol- and lucigenin-enhanced CL using a multichannel
luminometer (Biolumat LB 9505; Berthold Corp., Wildbad,
Germany). The details of this method have been described
earlier.38,41 Luminol was employed as a general detector that detects
various ROS, and lucigenin was used to detect superoxide anion
radical.42 The specificity of superoxide anion radical detection was
confirmed by subsequent quenching of the signal with SOD (30 U;
Sigma Chemicals) and 60 mM Mn(III) tetrakis (4-benzoic acid)
porphyrin chloride (Calbiochem, Schwalbach, Germany). The
obtained CL signal was expressed as counts/min and related to the
protein concentration determined in the samples after the CL
measurements.
Analysis of the enzymes
All assays on enzyme activities and Northern and Western analysis in
renal tissues have been previously described in detail.9,38,40 Briefly,
xanthine oxidase activity was determined by lucigenin-enhanced CL
detection of superoxide anion radical utilizing xanthine (Sigma
Chemicals) as a substrate. The specificity of the reaction was
confirmed by subsequent addition of oxypurinol (0.1 mM; Sigma
Chemicals). Results are expressed as counts/min per mg protein.
Total SOD activity, that is, copper/zinc SOD and manganese SOD,
was determined by cytochrome c reduction, and manganese SOD
activity was separately measured after addition of 1 mM potassium
cyanide to inhibit copper/zinc SOD. Results are given in U/mg
protein. Catalase activity was assayed spectrophotometrically by the
conversion rate of hydrogen peroxide. Results are expressed as mmol
H2O2/min mg protein. Glutathione peroxidase activity was deter-
mined by reaction of reduced glutathione with tert-butyl-hydroper-
oxide as a substrate, and subsequent reaction of the resulting
oxidized glutathione with NADPH (nicotinamide adenine dinucleo-
tide phosphate (reduced form)) and glutathione reductase. Results
are given as nmol NADPH/min mg protein. Protein determination
in the samples was performed by a modified Lowry’s method.43
For detection of xanthine oxidase by Western blotting, proximal
tubular samples containing 80 mg protein were separated on a 1.5-
mm-thick sodium dodecyl sulfate/8% polyacrylamide gel under
reducing conditions and blotted to nitrocellulose. The polyclonal
rabbit antibody against rat xanthine oxidase was a kind gift from
Takeshi Nishino (Nippon Medical School, Tokyo, Japan). After
probing for xanthine oxidase, blots were incubated with a polyclonal
rabbit antibody against human b-tubulin (Santa Cruz Biotechnol-
ogy Inc., Heidelberg, Germany), which was used as an internal
control for loading variances. The secondary antibody, anti-rabbit
IgG from donkey, was coupled to horseradish peroxidase and
detected with a CL kit (Amersham Biosciences, Freiburg, Germany).
Northern blotting was performed with 10 mg of total RNA from
proximal tubules, and xanthine oxidoreductase mRNA was detected
with a human xanthine oxidoreductase cDNA, kindly provided by
Mika Saksela (University of Helsinki, Finland).44 As an internal
control for loading variances, the 28S RNA levels were used.
Histological analysis
Tubulointerstitial damage was assessed in 3 mm sections stained with
periodic acid–Schiff. In each sample, 20 microscopic fields of cortical
tubulointerstitium were semiquantitatively evaluated at  200
magnification for tubular atrophy and tubulointerstitial fibrosis as
previously described in detail.9
To detect monocytes/macrophages, the mouse monoclonal
antibody to ED1 (Serotec/Camon, Wiesbaden, Germany) was used
on 3 mm methacarn-fixed sections. ED1-positive cells in the cortical
tubulointerstitium were counted in 30 microscopic fields at  400
magnification, beginning with a randomly chosen field followed by
the analysis of the adjacent fields in a meander-like fashion. Results
are given as mean number of positive cells per field. Xanthine
oxidase expression was detected on 3 mm methacarn-fixed sections
with a rabbit antibody against xanthine oxidase from rat liver that
had been purified by high-pressure liquid chromatography (Euro-
gentecs Belgium). MCP-1, ICAM-1, and VCAM-1 were detected on
frozen sections (4 mm) using polyclonal rabbit IgG against rat MCP-
1 (Torrey Pines Biolabs, San Diego, CA, USA), polyclonal goat IgGs
against human VCAM-1 (Santa Cruz Biotechnology Inc.), and
human ICAM-1 (Serotec). An alkaline phosphatase/anti-alkaline
phosphatase detection system was applied for all immune stainings
(Dako, Hamburg, Germany). Control experiments were performed
by omitting the primary antibody or taking the corresponding non-
immune serum instead of specific antibody.
Statistics
Quantitative measurements are given as means7s.d. Comparisons
between the groups were performed with the Wilcoxon’s U-test. A P-
value of o0.05 was considered as being statistically significant.
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